Europeiska unionen - estniska - EMA (European Medicines Agency)

chiesi farmaceutici s.p.a. - beclometasone dipropionate, formoterol dietüülfumaraat dihüdraat, glycopyrronium - kopsuhaigus, krooniline obstruktiivne - ravimid hingamisteede obstruktiivsete haiguste, - asendusravi keskmise või raske krooniline obstruktiivne kopsuhaigus (kok) täiskasvanud patsientidel, kes ei käsitleta piisavalt inhaleeritava kortikosteroidi ja pikatoimelise beta2-agonisti (mõju sümptomid kontrolli ja ägenemiste ennetamine vt lõik 5.

Europeiska unionen - estniska - EMA (European Medicines Agency)

astrazeneca ab - glycopyrronium, formoterol fumarate dihydrate - kopsuhaigus, krooniline obstruktiivne - formoterol ja glycopyrronium bromiid - bevespi aerosphere on näidustatud hooldus bronchodilator ravi, et leevendada sümptomeid täiskasvanud patsientidel, kellel on krooniline obstruktiivne kopsuhaigus (copd).

Estland - estniska - Ravimiamet

newline pharma s.l.u. - ipratroopiumbromiid - inhalatsiooniaerosool, lahus - 20mcg 1annus 200annus 3tk; 20mcg 1annus 200annus 1tk

Estland - estniska - Ravimiamet

fatro s.p.a. - rifaksimiin - intrauteriinvaht - 5,4mg 1ml 18.5ml 6tk

Estland - estniska - Ravimiamet

glaxosmithkline dungarvan limited - diklofenak - geel - 11,6mg 1g 75g 1tk; 11,6mg 1g 100g 1tk; 11,6mg 1g 50ml 1tk; 11,6mg 1g 20g 1tk; 11,6mg 1g 150g 1tk

Estland - estniska - Ravimiamet

fatro s.p.a. - tsefatsetriil+rifaksimiin - intramammaaremulsioon - 12,52mg+6,66mg 1g 15g 4tk

Estland - estniska - Ravimiamet

laboratorios hipra s.a. - kloortetratsükliin - nahasprei, suspensioon - 20mg 1ml 270ml 1tk

Estland - estniska - Ravimiamet

chiesi pharmaceuticals gmbh - salbutamool+beklometasoon - inhalatsiooniaerosool, suspensioon - 100mcg+250mcg 1annus 200annus 1tk

Europeiska unionen - estniska - EMA (European Medicines Agency)

astrazeneca ab - formoterol fumarate dihydrate, glycopyrronium bromide, budesonide - kopsuhaigus, krooniline obstruktiivne - ravimid hingamisteede obstruktiivsete haiguste, - trixeo aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long acting beta2 agonist or combination of a long-acting beta2 agonist and a long acting muscarinic antagonist.

Europeiska unionen - estniska - EMA (European Medicines Agency)

astrazeneca ab - budesonide, formoterol fumarate dihydrate, glycopyrronium bromide - kopsuhaigus, krooniline obstruktiivne - ravimid hingamisteede obstruktiivsete haiguste, - riltrava aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2 agonist or combination of a long-acting beta2 agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.